Filing Details

Accession Number:
0000950142-19-000290
Form Type:
13D Filing
Publication Date:
2019-02-15 16:05:40
Filed By:
Aisling Capital Iii Lp
Company:
Loxo Oncology Inc. (NASDAQ:LOXO)
Filing Date:
2019-02-15
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Aisling Capital III 0 0 0 0 0 0%
Aisling Capital Partners III 0 0 0 0 0 0%
Aisling Capital Partners III 0 0 0 0 0 0%
Steven Elms 0 0 0 0 0 0%
Dennis Purcell 0 0 0 0 0 0%
Andrew Schiff 0 0 0 0 0 0%
Filing


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

SCHEDULE 13D

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

RULE 13d-2(a)

(Amendment No. 5)*

 


Loxo Oncology, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

548862101

(CUSIP Number)

Robert Wenzel

Aisling Capital

888 Seventh Avenue, 12th Floor

New York, NY 10106

(212) 651-6380

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 14, 2019

(Date of Event which Requires Filing of this Statement)

 


 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

 

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


 
CUSIP No. 548862101
SCHEDULE 13D
Page 2 of 10

 
1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 

Aisling Capital III, LP

 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)  o
(b)  ☒
3
SEC USE ONLY
 
 
 
4
SOURCE OF FUNDS
 

OO

 
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 

Delaware

 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH
7
SOLE VOTING POWER
 

0

8
SHARED VOTING POWER
 

0

9
SOLE DISPOSITIVE POWER
 

0

10
SHARED DISPOSITIVE POWER
 

0

11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 

0

 
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
 
 
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 

0%

 
14
TYPE OF REPORTING PERSON
 

PN

 
 
 
CUSIP No. 548862101
SCHEDULE 13D
Page 4 of 10

 
1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 

Aisling Capital Partners III LLC

 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)  o
(b)  ☒
3
SEC USE ONLY
 
 
 
4
SOURCE OF FUNDS
 

OO

 
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 

Delaware

 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH
7
SOLE VOTING POWER
 

0

8
SHARED VOTING POWER
 

0

9
SOLE DISPOSITIVE POWER
 

0

10
SHARED DISPOSITIVE POWER
 

0

11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 

0

 
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
 
 
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 

0%

 
14
TYPE OF REPORTING PERSON
 

OO

 
 
 
CUSIP No. 548862101
SCHEDULE 13D
Page 5 of 10

 
1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 

Steven Elms

 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)  o
(b)  ☒
3
SEC USE ONLY
 
 
 
4
SOURCE OF FUNDS
 

OO

 
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 

United States

 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH
7
SOLE VOTING POWER
 

0

8
SHARED VOTING POWER
 

0

9
SOLE DISPOSITIVE POWER
 

0

10
SHARED DISPOSITIVE POWER
 

0

11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 

0

 
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
 
 
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 

0%

 
14
TYPE OF REPORTING PERSON
 

IN

 
 
CUSIP No. 548862101
SCHEDULE 13D
Page 6 of 10

 
1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 

Dennis Purcell

 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)  o
(b)  ☒
3
SEC USE ONLY
 
 
 
4
SOURCE OF FUNDS
 

OO

 
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 

United States

 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH
7
SOLE VOTING POWER
 

0

8
SHARED VOTING POWER
 

0

9
SOLE DISPOSITIVE POWER
 

0

10
SHARED DISPOSITIVE POWER
 

0

11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 

0

 
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
 
 
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 

0%

 
14
TYPE OF REPORTING PERSON
 

IN

 
 
 
CUSIP No. 548862101
SCHEDULE 13D
Page 7 of 10

 
1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 

Andrew Schiff

 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
 
(a)  o
(b)  ☒
3
SEC USE ONLY
 
 
 
4
SOURCE OF FUNDS
 

OO

 
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 

United States

 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH
7
SOLE VOTING POWER
 

0

8
SHARED VOTING POWER
 

0

9
SOLE DISPOSITIVE POWER
 

0

10
SHARED DISPOSITIVE POWER
 

0

11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 

0

 
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
 
 
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 

0%

 
14
TYPE OF REPORTING PERSON
 

IN

 
 
CUSIP No. 548862101
SCHEDULE 13D
Page 8 of 10

 

Item 1. Security and Issuer.

This Amendment No. 5 (this “Amendment”) to the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on May 27, 2016, as amended by Amendment No. 1 to the Schedule 13D filed with the SEC on January 12, 2017, Amendment No. 2 to the Schedule 13D filed with the SEC on November 22, 2017, Amendment No. 3 to the Schedule 13D filed with the SEC on July 10, 2018 and Amendment No. 4 to the Schedule 13D filed on January 15, 2019, relates to the Common Stock, $0.0001 par value (the “Shares”) of Loxo Oncology, Inc., a Delaware corporation (the “Issuer”) and is being filed to amend the Schedule 13D as specifically set forth below. The principal executive office of the Issuer is located at 281 Tresser Blvd., 9th Floor, Stamford, CT 06901.

This Amendment No. 5 is being filed to report that as of February 14, 2019, the Reporting Persons sold their entire interest in the Company and as such ceased to be the beneficial owners of more than five percent of the Common Stock of the Issuer.

Item 2. Identity and Background

No material change.

Item 3. Source and Amount of Funds or Other Consideration.

No material change.

Item 4. Purpose of Transaction.

Item 4 is hereby amended to add the following disclosure at the end of such item:

As previously disclosed, Aisling entered into a Tender and Support Agreement with Eli Lilly and Company and Bowfin Acquisition Corporation (“Merger Sub”), pursuant to which Aisling agreed to tender its Shares in the tender offer commenced by Merger Sub.  On February 14, 2019, the tender offer closed and Merger Sub accepted for purchase all of the Shares tendered by Aisling.

Item 5. Interest in Securities of the Issuer.

Item 5 is hereby amended and restated in its entirety as follows:

 

 

 

 

CUSIP No. 548862101
SCHEDULE 13D
Page 9 of 10

 

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

No material change.
Item 7. Materials to be filed as Exhibits.
No material change.
 
CUSIP No. 548862101
SCHEDULE 13D
Page 10 of 10

 

 

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 15, 2019

 
 
AISLING CAPITAL III, LP
 
 
 
 
 
 
By:
Aisling Capital Partners III, LP
General Partner
 
 
 
 
 
By:
Aisling Capital Partners III LLC
General Partner
 
 
 
 
 
 
 
 
By:
/s/ Dennis Purcell
 
 
 
 
Name: Dennis Purcell
 
 
 
 
Title: Managing Member
 
 
AISLING CAPITAL PARTNERS III, LP
 
 
 
 
 
 
By:
Aisling Capital Partners III LLC
General Partner
 
 
 
 
 
 
By:
/s/ Dennis Purcell
 
 
 
 
Name: Dennis Purcell
 
 
 
 
Title: Managing Member
 
 
AISLING CAPITAL PARTNERS III LLC
 
 
 
 
 
 
By:
/s/ Dennis Purcell
 
 
 
Name: Dennis Purcell
Title: Managing Member
 
 
 
 
 
 
 
/s/ Steven Elms
 
 
 
Steven Elms
 
 
 
 
 
 
 
/s/ Dennis Purcell
 
 
 
Dennis Purcell
 
 
 
 
 
 
 
/s/ Andrew Schiff
 
 
 
Andrew Schiff


Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).